Patent Extension Application for DAYVIGO (lemborexant) tablets, Patent No. 8,268,848 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2025-E-0707

Patent Extension Application for DAYVIGO (lemborexant) tablets, Patent No. 8,268,848

Documents

Comments

Description

OPEN

Comment Period OpensMar 13, 2025

Type	Title	Posted	Comments	Status
Other	Letter from U.S Patent and Trademark Office to FDA CDER	Mar 25, 2026	--

CDER

Patent Extension Application for DAYVIGO

Covington & Burling LLP

Eisai R&D Management Co., Ltd.

(lemborexant) tablets

Patent No. 8,268,848

OPEN